And here is the rub on this guidance regarding Twitter. Key takeaways from the guidance include new obligations that are not as onerous as expected. The opinions expressed on the blog are the opinions of the authors only and not those of Cooley LLP. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals. The use up pharma marketing blog post those intended use listed directly after five email. FDA's draft guidance on social media and off-label.